Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Core Points - Vor Biopharma Inc. has initiated an underwritten public offering of $100 million in common stock, with an additional option for underwriters to purchase up to $15 million more [1] - The offering is subject to market conditions and there is no guarantee on its completion or terms [1] - The shares are being offered under a shelf registration statement effective since March 31, 2025, and a preliminary prospectus will be filed with the SEC [3] Company Overview - Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [5] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development for serious autoantibody-driven conditions [5]